Tafamidis

Category Pipeline APIs

Details	Specifications
CAS Number	594839-88-0
Molecular Formula	C14H7Cl2NO3
Molecular Weight	308.11 g/mol.
Synonyms	2-(3,5-Dichlorophenyl) benzoxazole-6-carboxylic acid
Chemical Name	2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
Therapeutic use	Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.
Status	Tech pack available
Background	Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorization on 16 November 2011 and FDA approval on 3 May 2019.
Grade	In-house
Polymorph	Form I
Storage Temperature	Controlled room temperature (20?C ? 25?C)

Please Note: We partner exclusively with pharmaceutical manufacturers, biotech companies, and international trading firms. Minimum order quantities apply*

Disclaimer:

The information provided on this webpage is based on the best available knowledge at the time of publication; however, accuracy and completeness are not guaranteed. Product specifications may change without notice. It is the responsibility of the purchaser or user to verify suitability and compliance. This product is intended for research use only and is not approved for human consumption.

Why Shilpa Pharma?

Happy Customers

Projects Successfully Completed

Established

PhD Experts Driving R&D Excellence

Team Size

World-Class API Manufacturing Sites

Global Audits Successfully Completed

Comprehensive CDMO Service Offerings

Our Tafamidis are also Available for

Questions & Answers

FAQ on Tafamidis

Everything You Need to Know About Shilpa Pharma

Shilpa Pharma – Your Trusted Global CDMO Partner

Delivering end-to-end solutions across API oncology, generics, peptides, polymers and specialty chemicals, we empower partners to accelerate development, ensure compliance, and reach markets faster with reliable, cost-effective innovation.